Durysta Disease Interactions

Topically applied bimatoprost is systemically absorbed, then rapidly metabolized by the liver and eliminated by the kidney. Bimatoprost has not been adequately studied in the treatment of patients with impaired renal and/or hepatic function. Therapy with bimatoprost ophthalmic solution should be administered cautiously in such patients.

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic prostaglandin analogues. Most cases occurred in patients with aphakia, pseudophakia with a torn posterior lens capsule, or known risk factors for macular edema (e.g., posterior uveitis, certain retinal disorders). Therapy with ophthalmic prostaglandin analogues should be administered cautiously in these patients.

Bimatoprost, latanoprost, and travoprost are synthetic prostaglandin analogues. Theoretically, these agents may mimic endogenous prostaglandins and mediate ocular inflammatory responses. In clinical trials, uveitis and iritis have been reported rarely. Therapy with ophthalmic prostaglandin analogues should be administered cautiously in patients with active intraocular inflammation.